Amphastar Pharmaceuticals Earnings Calls

Q1 2025 Beat
$0.740 (12.12%)
Release date May 07, 2025
EPS estimate $0.660
EPS actual $0.740
EPS Surprise 12.12%
Revenue estimate 173.056M
Revenue actual 170.528M
Revenue Surprise -1.46%
Q4 2024 Missed
$0.92 (-8.91%)
Release date Feb 27, 2025
EPS estimate $1.01
EPS actual $0.92
EPS Surprise -8.91%
Revenue estimate 188.777M
Revenue actual 186.523M
Revenue Surprise -1.19%
Q3 2024 Missed
$0.96 (-3.03%)
Release date Nov 06, 2024
EPS estimate $0.99
EPS actual $0.96
EPS Surprise -3.03%
Revenue estimate 192.077M
Revenue actual 188.819M
Revenue Surprise -1.70%
Q2 2024 Beat
$0.94 (22.08%)
Release date Aug 07, 2024
EPS estimate $0.770
EPS actual $0.94
EPS Surprise 22.08%
Revenue estimate 170.94M
Revenue actual 182.394M
Revenue Surprise 6.70%

Last 4 Quarters for Amphastar Pharmaceuticals

Below you can see how AMPH performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q2 2024 Beat
Release date Aug 07, 2024
Fiscal end date Jun 30, 2024
Price on release $38.89
EPS estimate $0.770
EPS actual $0.94
EPS surprise 22.08%
Date Price
Aug 01, 2024 $42.45
Aug 02, 2024 $41.57
Aug 05, 2024 $40.41
Aug 06, 2024 $39.40
Aug 07, 2024 $38.89
Aug 08, 2024 $44.06
Aug 09, 2024 $42.85
Aug 12, 2024 $43.25
Aug 13, 2024 $43.56
4 days before -8.39%
4 days after 12.01%
On release day 13.29%
Change in period 2.61%
Q3 2024 Missed
Release date Nov 06, 2024
Fiscal end date Sep 30, 2024
Price on release $53.40
EPS estimate $0.99
EPS actual $0.96
EPS surprise -3.03%
Date Price
Oct 31, 2024 $50.53
Nov 01, 2024 $50.73
Nov 04, 2024 $50.59
Nov 05, 2024 $51.56
Nov 06, 2024 $53.40
Nov 07, 2024 $46.09
Nov 08, 2024 $48.31
Nov 11, 2024 $48.57
Nov 12, 2024 $47.71
4 days before 5.68%
4 days after -10.66%
On release day -13.69%
Change in period -5.58%
Q4 2024 Missed
Release date Feb 27, 2025
Fiscal end date Dec 31, 2024
Price on release $31.49
EPS estimate $1.01
EPS actual $0.92
EPS surprise -8.91%
Date Price
Feb 21, 2025 $31.28
Feb 24, 2025 $32.29
Feb 25, 2025 $31.99
Feb 26, 2025 $31.21
Feb 27, 2025 $31.49
Feb 28, 2025 $28.43
Mar 03, 2025 $27.52
Mar 04, 2025 $27.62
Mar 05, 2025 $28.06
4 days before 0.671%
4 days after -10.89%
On release day -9.72%
Change in period -10.29%
Q1 2025 Beat
Release date May 07, 2025
Fiscal end date Mar 31, 2025
Price on release $24.43
EPS estimate $0.660
EPS actual $0.740
EPS surprise 12.12%
Date Price
May 01, 2025 $23.88
May 02, 2025 $24.50
May 05, 2025 $25.12
May 06, 2025 $23.87
May 07, 2025 $24.43
May 08, 2025 $24.65
May 09, 2025 $24.11
May 12, 2025 $24.34
May 13, 2025 $23.88
4 days before 2.30%
4 days after -2.25%
On release day 0.90%
Change in period 0%

Amphastar Pharmaceuticals Earnings Call Transcript Summary of Q1 2025

Amphastar Pharmaceuticals Q1 Earnings Call Summary for Investors

Key Financial Highlights:

  • Revenue: Q1 net revenues totaled $170.5 million, a decline of 1% from the previous year. Factors contributing to the decline include increased competition affecting critical care products like Glucagon and Epinephrine.
  • Product Performance:
    • BAQSIMI: Revenues increased 177% to $38.3 million, attributed to Amphastar assuming full control over distribution after transitioning from Lilly.
    • Primatene MIST: Achieved sales of $29 million, marking a 20% growth compared to $24 million in Q1 of the previous year.
    • Glucagon Injection: Saw a significant decrease of 27% to $20.8 million due to heightened competition.
    • Epinephrine Sales: Declined 29% to $18.6 million also affected by competitive pressures.

Cost and Margins:

  • Cost of Revenues: Increased to $85.3 million, with a gross margin declining to 50% compared to 52.4% in Q1 of 2024. This decline is primarily due to the distribution shift for BAQSIMI and pricing pressures in competitive markets.
  • Net Income: Decreased to $25.3 million (or $0.51 per share), down from $43.2 million (or $0.81 per share) the previous year.

Strategic Developments:

  • Amphastar’s initiative to prevent drug shortages was acknowledged, earning the Drug Shortage Assistance Award from the USFDA.
  • Pipeline Focus: The company is optimistic about their pipeline, particularly the FDA communications regarding their drug AMP-002. Upcoming ANDA filings include:
    • AMP-007 (inhalation product) response planned for Q2.
    • AMP-015 (Teriparatide) expected to maintain GDUFA goal date in Q4.
    • AMP-018 (GLP-1 product) response to CRL expected in the second half of the year.

Market Outlook:

  • The regulatory landscape shows no significant delays in review times for complex generics, allowing for potential product launches later in the year which could support flat revenue expectations.
  • The company anticipates that ongoing competition in the Glucagon and Epinephrine markets will be a continuing challenge, while Primatene MIST and BAQSIMI are expected to drive revenue growth.

Tariff Implications:

  • Tariffs are monitored but any current impact is minimal, estimated at $500,000 per quarter due to imported active ingredients. The company is well-positioned given its domestic manufacturing capabilities.

Conclusion:

Overall, Amphastar Pharmaceuticals is navigating a challenging competitive environment but remains focused on strategic initiatives and expanding its drug portfolio. Key growth areas like BAQSIMI and Primatene MIST could offer opportunities to offset revenue pressures from other products. Investors may want to monitor the timeline of upcoming regulatory filings and product launches, as well as trends in competitive pressures across the portfolio.

Amphastar Pharmaceuticals Earnings History

Earnings Calendar

FAQ

When is the earnings report for AMPH?
Amphastar Pharmaceuticals (AMPH) has scheduled its earnings report for Aug 06, 2025 after the markets close.

What is the AMPH price-to-earnings (P/E) ratio?
AMPH P/E ratio as of May 16, 2025 (TTM) is 7.84.

What is the AMPH EPS forecast?
The forecasted EPS (Earnings Per Share) for Amphastar Pharmaceuticals (AMPH) for the first fiscal quarter 2025 is $0.710.

What are Amphastar Pharmaceuticals's retained earnings?
On its balance sheet, Amphastar Pharmaceuticals reported retained earnings of $170.53 million for the latest quarter ending Mar 31, 2025.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT AMPHASTAR PHARMACEUTICALS
Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Eno...
GOLDEN STAR
Ticker Change Signal Date
IEP
$8.75
11.43% May 09
JLL
$229.63
2.75% May 09
UAA
$5.84
14.90% May 09
IIPR
$54.61
4.30% May 09
MEDP
$300.81
1.61% May 08

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE